163
Views
32
CrossRef citations to date
0
Altmetric
Review

The recent advances of phenotypes in acute exacerbations of COPD

, , &
Pages 1009-1018 | Published online: 27 Mar 2017

Abstract

Exacerbations of COPD are clinically relevant events with therapeutic and prognostic implications. Yet, significant heterogeneity of clinical presentation and disease progression exists within acute exacerbations of COPD (AECOPD). Currently, different phenotypes have been widely used to describe the characteristics among patients with AECOPD. This has proved to be significant in the treatment and prediction of the outcomes of the disease. In this review of published literature, the phenotypes of AECOPD were classified according to etiology, inflammatory biomarkers, clinical manifestation, comorbidity, the frequency of exacerbations, and so on. This review concentrates on advancements in the use of phenotypes of AECOPD.

Introduction

AECOPD is an acute event characterized by a worsening of the patient’s respiratory symptoms that is beyond normal day-to-day variation and leads to change in medication.Citation1 At first glance, this definition seems straightforward. However, it has several caveats and unknowns that differ according to each patient’s pathobiological heterogeneity and different clinical presentation and management needs.

COPD phenotype is defined as “a single or combination of disease attributes that describe differences between individuals with COPD as they relate to clinically meaningful outcomes”. Therefore, the phenotype should be able to be used to classify patients into subgroups with a prognostic value that allows determining the best treatment in order to achieve better clinical results.Citation2 In this way, we can take on a more personalized treatment according to the severity of the airflow obstruction and conditioned by the clinical phenotype. Recent findings suggest that exacerbations of COPD are heterogeneous events and that this heterogeneity might have clinically relevant therapeutic and prognostic effects.Citation3 In a viewpoint published in the journal The Lancet Respiratory Medicine,Citation4 the authors proposed a two-axis classification of exacerbations of COPD by considering the pathobiological and clinical heterogeneity of exacerbations of COPD. They stratified patients into four groups (E1–E4), each of which might need a different treatment strategy and have a different short-term risk, and hence the need for a different care setting. Unfortunately, phenotype in AECOPD is still in a stage of exploration. It has always been classified based on different etiologies, clinical manifestations, biomarkers, comorbidities, frequencies of exacerbation, and so on. In this review, we mainly focus on the phenotypes that have been proven to have a therapeutic or prognostic effect on patients with AECOPD.

Methods

Search strategy

A review was performed to identify research articles or meta-analysis from 1986 to 2016 that assessed the characteristics, including etiology, manifestation, inflammatory cells, comorbidity, and frequency of exacerbation, which are related to different therapies or prognosis of patients with AECOPD. This review was performed on September 5, 2016, in PubMed. The search strategy is shown in .

Table 1 Search strategy

Eligibility criteria for study selection

Studies including articles or meta-analysis that focused on any one of the characteristics associated with different therapies or prognosis of the patients with AECOPD were included. Patients must be subjects older than 40 years diagnosed with AECOPD. Articles were excluded if they did not show the different traits based on the phenotypes, subgroups, or heterogeneity. Studies that tested empirically defined phenotypes without an analytical justification of these phenotypes and those that concentrated on the phenotypes in stable COPD were excluded. Moreover, the abstracts of the articles not published in English were excluded. Two independent authors (AZ and ZZ) reviewed the title and abstract against the inclusion criteria. Disagreements between reviewers were resolved through the third reviewer by discussion.

Etiology phenotypes

It is well known that AECOPD may be triggered by infection with bacteria or viruses or by noninfectious environmental (eg, temperature, pollution, allergens, and diet) or internal (immune dysregulation) factors. The cause of approximately one-third of exacerbations cannot be identified.Citation5Citation7 Patients with detectable respiratory pathogens have been shown to exhibit a more marked impact on lung function and longer duration of hospitalization than patients with exacerbations of noninfectious etiology.Citation8 With in-depth studies of microorganisms, some research concludes that there are differences in the clinical manifestation, treatment, and prognosis between bacterial infections and viral infections. Sore throat, cough, dyspnea, and chills are more common in viral infections than in bacterial infections.Citation9 Viral exacerbations are associated with higher IL-6 levels,Citation10 lower levels of CRP,Citation11 and longer duration of hospital stay (average 9 days).Citation12 However, as for antiviral treatment, the current therapies for the virus-induced exacerbations are not very effective.Citation12 The guideline about the lower respiratory tract infection treatment published in 2011 by the European Respiratory Society pointed out that AECOPD patients usually were not recommended to have empiric antiviral treatment. However, if in flu season, or at high risk of flu, patients with typical influenza symptoms (such as fever, muscle pain, muscle weakness, and respiratory infection symptoms), if onset is within 2 days, should have antiviral treatment as early as possible.Citation13 In bacterial exacerbations, purulent sputum is the typical symptom, as is neutrophil inflammation in both blood and airway. Levels of CRP and PCT would be higher than those in non-bacterial exacerbations.Citation14 Cited guidelines suggest that exacerbations of COPD with purulence of sputum are the most important symptom, which calls for the use of antibiotics.Citation15,Citation16 Altogether, knowing the characteristics of various etiologies may have important therapeutic implications and provide evidence for local surveillance of AECOPD pathogens and appropriate choice of antimicrobials. This may give clinicians some indications to avoid abusing antibiotics to some extent.

Inflammatory phenotypes

Patients with AECOPD also display heterogeneous inflammation. At present, the diagnosis of AECOPD mainly depends on clinical symptoms. There is lack of quantitative indicators. Inflammatory markers as a kind of quantitative indicator are widely used in judging acute exacerbation and assessing prognosis. Systemic inflammatory markers mainly include CRP,Citation17Citation19 PCT,Citation20,Citation21 serum amyloid A,Citation22 SP-D,Citation23 fibrinogen,Citation24 inflammation cell chemotactic factor,Citation25 and so on. All the markers mentioned earlier will increase in AECOPD patients and decrease in recovery. As a result of these investigations using biomarkers, the patients were divided into different phenotypes.

CRP is one of the most important biomarkers. A small study reported that a cutoff value of 19.65 mg/L has a sensitivity of 78% and a specificity of 84% to identify the bacterial origin of exacerbations of COPD. In patients with AECOPD with mucoid sputum, an elevated CRP level of >15.21 mg/L indicates bacterial infection.Citation18 However, a study published recently found that PCT and CRP cannot differentiate between bacterial and viral infections in the exacerbations of COPD requiring emergency department visits.Citation26 Another study showed that CRP >100 mg/mL was associated with a near fourfold increased probability of adverse outcome.Citation27 PCT is also a very important marker in AECOPD. PCT level >0.5 ng/mL is independently associated with bacterial isolation in severe AECOPD.Citation21,Citation28 In addition, in patients who required intubation and mechanical ventilation, PCT levels are independently associated with increased risk for ICU mortality.Citation21 Yet, a post hoc analysis of a randomized, placebo-controlled trial that failed to show a positive effect of antibiotics in COPD exacerbations suggested that patients with low PCT concentrations during a COPD exacerbation might also benefit from antibiotic treatment.Citation29 Above all, the results from a meta-analysis suggest that PCT-guided treatment can safely reduce antibiotic overuse in patients with AECOPD,Citation30 but the cutoff of PCT to use antibiotics has no consensus; further studies are needed to evaluate the utility of PCT measurement.Citation31

Some biomarkers, such as fibrinogen,Citation32,Citation33 TNT,Citation34 VEGF,Citation35 4-HNE,Citation36 PF4,Citation37 β-thromboglobulin,Citation38 and copeptin,Citation19 may also reflect the severity of AECOPD and can be used as prognostic markers. However, there is no cut point enabling these markers to differentiate between patients with different phenotypes. In the period of AECOPD, the airway inflammation is more severe than that in stable COPD. The most widely used biomarkers of airway inflammation are FeNO and induced sputum analysis. Currently, FeNO is regarded as the most promising indicator.Citation39 Some studies have reported that patients with high FeNO levels will have a good response to corticosteroids and greater improvement in FEV1.Citation39,Citation40 The reason for this result may be due to the fact that the FeNO level correlated well with the eosinophils, which is a good predictor for the response to corticosteroids.Citation41,Citation42 Antus et alCitation43 pointed out that the optimum cutoff point for FENO as a predictor for significant increase in FEV1 was 26.8 ppb (sensitivity: 74% and specificity: 75%). In addition, induced sputum analysis has beneficial effects on the treatment and prognosis of patients with AECOPD. Patients can be divided into different phenotypes according to the type of inflammatory cells. These inflammatory phenotypes are clinically relevant due to potential differences in the response to therapeutic interventions. Gao et alCitation44 recently identified the following four subgroups: eosinophilic predominant, neutrophilic predominant, paucigranulocytic predominant, and mixed granulocytic predominant. The eosinophilic phenotype (EO) is so named when sputum eosinophils are >2.5% of total cells, the neutrophilic phenotype (NE) is the subgroup having neutrophils >61%, the paucigranulocytic phenotype (PA) has eosinophils ≤2.5% and neutrophils ≤61%, and the mixed granulocytic phenotype (MC) has eosinophils >2.5% and neutrophils >61%. Different phenotypes have different pathological and physiological characteristics. The results of this study showed that the patients with mixed granulocytic or neutrophilic AECOPD had a higher BODE score, more sputum inflammatory cells, lower lung function, and longer hospital stay, accompanied by higher concentrations of sputum MMP-9, IL-6, and CRP and serum SAA, IL-6, and CRP. Notably, 83% of patients with neutrophilic AECOPD displayed evidence of bacterial infection and many of them responded poorly to standard therapies. Patients with EO, especially when combined with asthma, have a better response to corticosteroids than the rest of the other types.Citation45 Similar results were later reported by Bafadhel et al.Citation46 Therefore, the classification of inflammatory cells in sputum and the level of FeNO are of great importance in assessing the prognosis of patients and guiding whether or not to use corticosteroids. However, although the identification of inflammatory phenotype is meaningful for AECOPD, the sensitivity, specificity, and multiindex application of this method on the efficiency of the diagnosis remain to be further studied.Citation47

Clinical manifestation of phenotypes

As mentioned earlier, AECOPD is a heterogeneous disease and this heterogeneity can also be reflected in the symptoms. In exacerbations, the most important symptoms are increased dyspnea, sputum volume, and sputum purulence. Nowadays, the recognized criterion used to classify AECOPD according to symptoms is the Anthonisen standard.Citation48 Anthonisen et alCitation48 divided exacerbations into three types. Type 1 exacerbations involve increased dyspnea, sputum volume, and sputum purulence, Type 2 involve any two of the latter symptoms, and Type 3 just involves one of those symptoms combined with cough, wheeze, or symptoms of an upper respiratory tract infection. In Type 1 exacerbations, patients had an improved response to the antibiotic therapy and the CRP level in Type 1 was more elevated than in the other two types. It is recommended that antibiotics are used as early as possible in Type 1 exacerbations.Citation49 Moreover, Stockley et alCitation50 found that the presence of green (purulent) sputum indicates a clear subset of patients identified at presentation who are likely to benefit most from antibiotic therapy. In addition, before an episode of exacerbation, the prodromes are different among patients. Aaron et alCitation51 divided the exacerbations of COPD into two distinct patterns, such as sudden and gradual onsets, according to worsening respiratory symptoms from diary cards. Patients who experienced sudden onset exacerbations had greater mean daily symptom scores, greater peak symptom scores, earlier peak symptoms, and shorter median recovery times back to baseline health status. Above all, these prodromes are important in differentiating the triggers of exacerbations. For instance, dyspnea, common colds, sore throat, and cough increase significantly during the prodromal phase, indicating that the triggers are more likely to be viral. Colds are even associated with longer and more severe exacerbations, and there is no doubt that a COPD patient who develops a cold should be considered for early therapy.Citation52

It is well known that the severity of COPD is assessed not only by lung function, but CAT, mMRC questionnaires, and CCQ also have great importance in assessing the disease severity and estimating the risk of exacerbations. In GOLD 2013, CAT and mMRC were used for grading and different grades corresponded to different treatments.Citation53 According to the clinical manifestation of the phenotype, the clinician can therefore provide more purposeful and individualized treatment.

Comorbidity phenotypes

AECOPD is often accompanied by comorbidities, which include not only the pulmonary disease but also the extrapulmonary disease. Comorbidities during hospital admission are associated with increased length of stay, mortality, and poor outcomes in patients with AECOPD.Citation54 In terms of the pulmonary comorbidity, it is very common to see a great number of patients who suffer COPD accompanied by asthma,Citation55 pneumonia,Citation56 and lung cancer.Citation57 Patients having the characteristics that are attributed to both COPD and asthma are called mixed phenotypes. A study has shown that between 20% and 40% of COPD patients can be carriers of a mixed phenotype.Citation55 This newly described phenotype is called as the ACOS.Citation58,Citation59 Patients with a history of asthma are more likely to have a good response to corticosteroids,Citation55 and the FEV1 decreased faster than that in patients who have no asthma.Citation60 Furthermore, in GOLD 2014, bronchiectasis has been added to the comorbidities of COPD. Patients with the diagnosis of COPD who share the comorbidity of bronchiectasis will experience longer exacerbations. The pathogens in patients with AECOPD and bronchiectasis are complex and will usually need broad-spectrum antibiotics.Citation61,Citation62

COPD can no longer be considered as a disease, which only affects the lungs. Increasing evidence supports the presence of a systemic inflammatory component, which is thought to provide the link between COPD and other extrapulmonary comorbidities.Citation63,Citation64 These include cardiovascular disorders, skeletal muscle dysfunction, diabetes, osteoporosis, anxiety, and depression.Citation65Citation68 Similarly, a multicenter Spanish study identified four COPD exacerbation types (subtypes A–D, classified on the basis of their clinical severity and presence or absence of comorbidities). Patients with these different subtypes of the disease required different hospital setting needs (regular ward vs intensive care unit): subtype A (n=934), neither high comorbidity nor severe exacerbation; subtype B (n=682), moderate comorbidities; subtype C (n=562), severe comorbidities related to mortality; and subtype D (n=309), very severe exacerbation significantly related to mortality and admission to an intensive care unit. Subtype D experienced the highest rate of mortality, admission to an intensive care unit, and need for noninvasive mechanical ventilation. This was closely followed by subtype C, while subtypes A and B were primarily related to other serious complications. Hospitalization rate was >50% for all the subtypes, although significantly higher for subtypes C and D than for subtypes A and B.Citation69 These results could help to identify characteristics in order to categorize AECOPD patients for more appropriate care. They could also help in assessing interventions and treatments in subgroups with poor evolution and outcomes.

Frequent exacerbations phenotypes

The frequency of AECOPD is variable among patients. Recently, a “frequent exacerbator” phenotype has been postulated and examined in clinical studies. The pathophysiology underlying the frequent exacerbations phenotype includes increased airway and systemic inflammation, dynamic lung hyperinflation, changes in lower airway bacterial colonization, increased susceptibility to viral infection, and increased risk from comorbid extra pulmonary diseases. However, as for the definition of frequent exacerbators, there is no uniform standard at present. Most clinical research defined frequent exacerbators as those having a greater number of exacerbations than the median of the study population every year, those needing a course of oral antibiotics or oral glucocorticoid therapy, or those who needed to be hospitalized twice a year because of acute exacerbations.Citation70,Citation71 In the ECLIPSE study of COPD exacerbation susceptibility, ~20% of patients with GOLD stage II disease and as many as 47% of those with stage IV disease were classified as frequent exacerbators (defined as two or more exacerbations annually). A previous study has shown that patients with frequent exacerbations and those with infrequent exacerbations tended to remain in the same category of exacerbation frequency for the full 3 years of the study, although a few patients may have shifted from one category to another.Citation70 This stability could suggest that the frequency of exacerbations is related to the susceptibilities of the patients. A recent review has concluded the possible reasons for the frequency of AECOPD. It concludes that high levels of inflammation, high susceptibility to viral infection and bacterial colonization, fast FEV1, functional decline, poor health care status, and worsened comorbidity will increase the risk of exacerbation.Citation72 Moreover, other studies also pointed out some meaningful factors that are related to the frequency, as listed in . Patients with a history of frequent exacerbations have an increased rise in both systemic inflammation and airway inflammation,Citation73,Citation74 more rapid decline of lung function, worse quality of life,Citation75 and higher mortality ratesCitation76,Citation77 compared to patients with infrequent exacerbations. However, the classification of these frequent exacerbations phenotype is based on clinical records and/or patient recall, and the history of exacerbations is provided by the patients themselves. It is therefore important to ask about the history of exacerbations in the clinical interview in order to identify patients who may require anti-inflammatory medication. The treatment recommended in GOLD is also different for frequent exacerbators, such as long-term inhalation of corticosteroids. Adopting anti-inflammatory and anti-infection treatments in frequent exacerbators may be nontherapeutic. In the summary of the GesEPOC,Citation78 the frequent exacerbators are further divided into the following two types: those with emphysema predominant and those with chronic bronchitis predominant. The treatment for the two types is also different. For the emphysema phenotype, the basis of pharmacological treatment is long-acting bronchodilators, and in some cases with ICS. The bronchitis-predominant exacerbator patients may be treated with bronchodilators and ICS, and in contrast to exacerbators with emphysema, they respond to treatment with Roflumilast. Selected cases with frequent exacerbations may respond to long-term treatment with macrolides,Citation79 and when ICS cannot be used, mucolytics may be effective in reducing exacerbations.Citation80 However, another study shows that whatever the declining degree of lung function, it is recommended that patients with frequent exacerbations use ICS combined with bronchial relaxation, which can significantly reduce the number of exacerbations and improve the quality of life.Citation81 The use of ICS is still a hot topic that needs large-scale, randomized, double-blind, controlled studies in order to assess its effectiveness. In summary, the frequent exacerbation phenotype as a distinct phenotype is of great significance and clinicians could develop a professional treatment for these patients, which can be used for health economic purposes.Citation82

Table 2 The factors related to the frequency of exacerbations

Discussion

The literature relating to AECOPD phenotypes in this review mainly focuses on the significant heterogeneity among the patients. The Anthonisen standardCitation48 based on clinical manifestations (published in 1987) was the most widely recognized classification in many studies and is thought to have clinical implications. Clinicians may speculate on the kind of etiology, draw up an individual therapy protocol, and also evaluate the prognosis of patients with AECOPD according to their clinical manifestations. In an in-depth study of microorganisms, a respiratory infectious phenotype was classified by Dai et alCitation8 who found that respiratory infectious phenotypes are associated with a greater length of stay in hospital and greater severity of symptoms in AECOPD. However, this study did not check all the relevant factors or diseases associated with a prolonged stay in hospital, which therefore may have affected their results. Further investigation is needed to assess the clinical implication of this phenotype. In terms of inflammatory phenotype, two studiesCitation44,Citation46 classified AECOPD patients with inflammatory cells or biomarkers. Nevertheless, there are some differences between the classifications; in the study conducted by Gao et al,Citation44 the patients were sorted into four groups, including EO, NE, PA, and MC. They conclude that there are some differences among these groups. While another studyCitation46 used cluster analysis to classify the patients into bacteria, virus, and eosinophil groups based on biomarkers. In this study, they used two methods to investigate biomarkers in AECOPD. The first method used unbiased statistical tools, identified biological COPD exacerbation phenotypes, and characterized exacerbations into four biological clusters, while the second method employed the currently used clinical exacerbation phenotypes of COPD related to potential etiology and inflammation (namely exacerbations that are associated with bacteria, virus, or a sputum eosinophilia). The biological exacerbation clusters were bacterial, viral, eosinophilic-predominant, and pauci-inflammatory. It was found that these clusters were remarkably similar to the clinical exacerbation phenotypes. Thus, in addition to identifying potential biomarkers to direct therapy and evaluate prognosis, these clinical exacerbation phenotypes are likely to represent distinct pathophysiological entities with specific biomarker signatures. In studies concerned with the comorbidity phenotype, Arostegui et alCitation69 characterized the AECOPD patients into four types according to the severity of the current exacerbation and the comorbidities. Subtype D (defined as having very severe exacerbations with low or mild comorbidity) was significantly related to mortality and admission to an intensive care unit. Although this study did not offer detailed suggestions for the treatment of AECOPD, it evoked awareness in clinicians of the need to treat patients comprehensively. It was reported that the frequent exacerbations were related to many factors, as is well known. The current GOLD classification of COPD acknowledges the complexity of the disease, and the frequency of the exacerbation is also considered when classifying patients. It was suggested that patients with frequent exacerbations should have treatment with ICS. However, the definition of the frequent exacerbator and the subjects themselves varied among the studies. In a retrospective study, the frequency of the exacerbation could be influenced by the memory of the patients. In addition, there are some unreported exacerbations. Due to the difference in the frequency, the range of the patients who should be treated with ICS would be different too. Thus, in terms of the use of ICS, it requires large-scale, randomized, double-blind, controlled studies to gather more evidence supporting its use.

Limitations of our review include the following: the language restriction that articles not published in English were excluded in this review may induce a language bias. Moreover, the studies were extracted only from PubMed, which may result in missing some articles; nevertheless, we also make a simple glance over the articles related to the phenotypes of AECOPD in Web of Science and Embase, and there are no crucial studies that were not selected in the review. Another limitation is that we excluded studies that focused on the phenotypes in stable COPD. This may remove a potential phenotype from our review, which may also have prognostic value in the exacerbations of COPD. However, the exclusion was as per protocol, with the aim of producing a review, which is focused on answering a specific question related solely to AECOPD.

Conclusion

AECOPD is a heterogeneous disease. Investigations of the different phenotypes of AECOPD have resulted in the definition of different types of patients with prognostic and therapeutic significance. Because the diversity of the phenotypes of each condition is better understood, clinicians will be presented with opportunities to evolve from a “one size fits all” approach to personalized approaches, with the ultimate goal of improving care and reducing potential adverse effects from unnecessary therapies.Citation83 However, research into AECOPD phenotypes is still in its infancy, and with a detailed study of the phenotypes of AECOPD, it is possible that a new phenotype allowing individualized treatment and estimation of prognosis will be found. This means that there is an urgent need for well-designed clinical studies focused on AECOPD phenotypes.

Abbreviations

ACOS=

asthma–COPD overlap syndrome

AECOPD=

acute exacerbations of COPD

BODE=

body mass index, airflow obstruction, dyspnea, and exercise capacity

CAT=

COPD Assessment Test

CCQ=

Clinical COPD Questionnaire

CRP=

C-reactive protein

ECLIPSE=

Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints

FeNO=

fractional exhaled nitric oxide

FEV1=

forced expiratory volume in 1 second

GesEPOC=

Spanish COPD guidelines

GOLD=

Global Initiative for Chronic Obstructive Lung Disease

4-HNE=

4-human neutrophil elastase

ICS=

inhaled corticosteroids

ICU=

intensive care unit

IL-6=

interleukin-6

MBL=

mannose-binding lectin

MMP-9=

matrix metalloproteinase-9

mMRC=

modified medical research council

MPO=

myeloperoxidase

NETT=

National Emphysema Treatment Trial

PF4=

platelet factor 4

PCT=

procalcitonin

SAA=

serum amyloid protein A

SP-D=

serum surfactant protein-D

TNT=

troponin-T

VEGF=

vascular endothelial growth factor

Acknowledgments

This study was supported by grants from the National Natural Science Foundation of China (NSFC; Grants 81370143 to Professor Ping Chen).

Disclosure

The authors report no conflicts of interest in this work.

References

  • VestboJHurdSSAgustiAGGlobal strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summaryAm J Respir Crit Care Med2013187434736522878278
  • HanMKAgustiACalverleyPMChronic obstructive pulmonary disease phenotypes: the future of COPDAm J Respir Crit Care Med2010182559860420522794
  • HurstJRExacerbation phenotyping in chronic obstructive pulmonary diseaseAm J Respir Crit Care Med2011184662562621920921
  • Lopez-CamposJLAgustiAHeterogeneity of chronic obstructive pulmonary disease exacerbations: a two-axes classification proposalLancet Respir Med20153972973426165134
  • BurgeSWedzichaJACOPD exacerbations: definitions and classificationsEur Respir J Suppl20034146s53s12795331
  • CelliBRBarnesPJExacerbations of chronic obstructive pulmonary diseaseEur Respir J20072961224123817540785
  • BegheBVerduriARocaMFabbriLMExacerbation of respiratory symptoms in COPD patients may not be exacerbations of COPDEur Respir J201341499399523543648
  • DaiMYQiaoJPXuYHFeiGHRespiratory infectious phenotypes in acute exacerbation of COPD: an aid to length of stay and COPD Assessment TestInt J Chron Obstruct Pulmon Dis20151012257226326527871
  • WedzichaJADonaldsonGCExacerbations of chronic obstructive pulmonary diseaseRespir Care2003481212041213 discussion 1213–121514651761
  • RohdeGBorgIWiethegeAInflammatory response in acute viral exacerbations of COPDInfection200836542743318795228
  • GarchaDSThurstonSJPatelARChanges in prevalence and load of airway bacteria using quantitative PCR in stable and exacerbated COPDThorax201267121075108022863758
  • DimopoulosGLerikouMTsiodrasSViral epidemiology of acute exacerbations of chronic obstructive pulmonary diseasePulm Pharmacol Ther2012251121821983132
  • WoodheadMBlasiFEwigSJoint Taskforce of the European Respiratory Society and European Society for Clinical Microbiology and Infectious DiseasesGuidelines for the management of adult lower respiratory tract infections – full versionClin Microbiol Infect201117Suppl 6E1E59
  • TanriverdiHOrnekTErboyFComparison of diagnostic values of procalcitonin, C-reactive protein and blood neutrophil/lymphocyte ratio levels in predicting bacterial infection in hospitalized patients with acute exacerbations of COPDWien Klin Wochenschr201512719–2075676325586444
  • O’DonnellDEAaronSBourbeauJCanadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease – 2007 updateCan Respir J200714Suppl B5B32B
  • PauwelsRABuistASCalverleyPMJenkinsCRHurdSSGlobal strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) workshop summaryAm J Respir Crit Care Med200116351256127611316667
  • KaradenizGPolatGSenolGBuyuksirinMC-reactive protein measurements as a marker of the severity of chronic obstructive pulmonary disease exacerbationsInflammation201336494895323547018
  • PengCTianCZhangYYangXFengYFanHC-reactive protein levels predict bacterial exacerbation in patients with chronic obstructive pulmonary diseaseAm J Med Sci2013345319019423221507
  • StolzDChrist-CrainMMorgenthalerNGCopeptin, C-reactive protein, and procalcitonin as prognostic biomarkers in acute exacerbation of COPDChest200713141058106717426210
  • CortiCFallyMFabricius-BjerreAPoint-of-care procalcitonin test to reduce antibiotic exposure in patients hospitalized with acute exacerbation of COPDInt J Chron Obstruct Pulmon Dis2016111381138927382274
  • RammaertBVerdierNCavestriBNseirSProcalcitonin as a prognostic factor in severe acute exacerbation of chronic obstructive pulmonary diseaseRespirology200914796997419659517
  • BozinovskiSHutchinsonAThompsonMSerum amyloid a is a biomarker of acute exacerbations of chronic obstructive pulmonary diseaseAm J Respir Crit Care Med2008177326927818006888
  • Zien AlaabdenAMohammadYFahoumSThe role of serum surfactant protein D as a biomarker of exacerbation of chronic obstructive pulmonary diseaseQatar Med J2015201521826942111
  • WangSChenYRenW益气活血法对慢性阻塞性肺疾病 急性加重患者血浆纤维蛋白原及 D – 二聚体的影响 [Effect of Qi benefiting blood activating method on plasma fibrinogen and D-dimer in patients with acute exacerbation of chronic obstructive pulmonary disease]Zhongguo Zhong Xi Yi Jie He Za Zhi2015355537540 Chinese26159014
  • PapiABellettatoCMBraccioniFInfections and airway inflammation in chronic obstructive pulmonary disease severe exacerbationsAm J Respir Crit Care Med2006173101114112116484677
  • ClarkTWMedinaMJBathamSCurranMDParmarSNicholsonKGC-reactive protein level and microbial aetiology in patients hospitalised with acute exacerbation of COPDEur Respir J2015451768625186260
  • TofanFRahimi-RadMHRasmiYRahimiradSHigh sensitive C-reactive protein for prediction of adverse outcome in acute exacerbation of chronic obstructive pulmonary diseasePneumologia201261316016223175870
  • NseirSCavestriBDi PompeoCFactors predicting bacterial involvement in severe acute exacerbations of chronic obstructive pulmonary diseaseRespiration200876325326018547944
  • DanielsJMSchoorlMSnijdersDProcalcitonin vs C-reactive protein as predictive markers of response to antibiotic therapy in acute exacerbations of COPDChest201013851108111520576731
  • LinCPangQMeta-analysis and systematic review of procalcitonin-guided treatment in acute exacerbation of chronic obstructive pulmonary diseaseClin Respir J Epub2016622
  • ZhangLHuangJXuTLinY降钙素原指导抗生素治疗策略 在社区获得性下呼吸道感染巾应用的荟萃分析 [Procalcitonin-guided algorithms of antibiotic therapy in community-acquired lower respiratory tract infections: a systematic review and meta-analysis of randomized controlled trials]Zhonghua Jie He He Hu Xi Za Zhi2012354275282 Chinese22781200
  • GroenewegenKHPostmaDSHopWCIncreased systemic inflammation is a risk factor for COPD exacerbationsChest2008133235035718198263
  • WedzichaJASeemungalTAMacCallumPKAcute exacerbations of chronic obstructive pulmonary disease are accompanied by elevations of plasma fibrinogen and serum IL-6 levelsThromb Haemost200084221021510959691
  • HoisethADNeukammAKarlssonBDOmlandTBrekkePHSoysethVElevated high-sensitivity cardiac troponin T is associated with increased mortality after acute exacerbation of chronic obstructive pulmonary diseaseThorax201166977578121653926
  • ValipourASchrederMWolztMCirculating vascular endothelial growth factor and systemic inflammatory markers in patients with stable and exacerbated chronic obstructive pulmonary diseaseClin Sci (Lond)2008115722523218307413
  • LiuHXuJY4一羟基壬烯醛在慢性阻塞性肺疾病严重程度评估 中的作用 [The role of 4-hydroxynonenal in assessment of chronic obstructive pulmonary disease severity]Zhonghua Jie He He Hu Xi Za Zhi20123510758761 Chinese23289993
  • WuJFYangYHPangBS慢 性 阻 塞 性 肺 疾 病 急 性 加 重 患 者 血 浆 血 小 板 因 子 4及 13凝 血 球 蛋 白 水 平 的 变 化 及 其 意 义 [Platelet factor 4 and beta-thromboglobulin in blood plasma of patients with acute exacerbation of chronic obstructive pulmonary disease]Zhonghua Yi Xue Za Zhi2013931813781382 Chinese24025501
  • KaradagFKarulABCildagOYilmazMOzcanHBiomarkers of systemic inflammation in stable and exacerbation phases of COPDLung2008186640340918807087
  • DummerJFEptonMJCowanJOPredicting corticosteroid response in chronic obstructive pulmonary disease using exhaled nitric oxideAm J Respir Crit Care Med2009180984685219661244
  • KunisakiKMRiceKLJanoffENRectorTSNiewoehnerDEExhaled nitric oxide, systemic inflammation, and the spirometric response to inhaled fluticasone propionate in severe chronic obstructive pulmonary disease: a prospective studyTher Adv Respir Dis200822556419124359
  • AminKJansonCBystromJRole of eosinophil granulocytes in allergic airway inflammation endotypesScand J Immunol2016842758527167590
  • DonohueJFHerjeNCraterGRickardKCharacterization of airway inflammation in patients with COPD using fractional exhaled nitric oxide levels: a pilot studyInt J Chron Obstruct Pulmon Dis2014974575125053884
  • AntusBBartaIHorvathICsiszerERelationship between exhaled nitric oxide and treatment response in COPD patients with exacerbationsRespirology201015347247720210889
  • GaoPZhangJHeXHaoYWangKGibsonPGSputum inflammatory cell-based classification of patients with acute exacerbation of chronic obstructive pulmonary diseasePLoS One201385e5767823741289
  • van VeenIHTen BrinkeAGauwSASterkPJRabeKFBelEHConsistency of sputum eosinophilia in difficult-to-treat asthma: a 5-year follow-up studyJ Allergy Clin Immunol20091243615617617.e1617.e219733302
  • BafadhelMMcKennaSTerrySAcute exacerbations of chronic obstructive pulmonary disease: identification of biologic clusters and their biomarkersAm J Respir Crit Care Med2011184666267121680942
  • LacomaAPratCAndreoFValue of procalcitonin, C-reactive protein, and neopterin in exacerbations of chronic obstructive pulmonary diseaseInt J Chron Obstruct Pulmon Dis2011615716921468168
  • AnthonisenNRManfredaJWarrenCPHershfieldESHardingGKNelsonNAAntibiotic therapy in exacerbations of chronic obstructive pulmonary diseaseAnn Intern Med198710621962043492164
  • StolzDChrist-CrainMBingisserRAntibiotic treatment of exacerbations of COPD: a randomized, controlled trial comparing procalcitonin-guidance with standard therapyChest2007131191917218551
  • StockleyRAO’BrienCPyeAHillSLRelationship of sputum color to nature and outpatient management of acute exacerbations of COPDChest200011761638164510858396
  • AaronSDDonaldsonGCWhitmoreGAHurstJRRamsayTWedzichaJATime course and pattern of COPD exacerbation onsetThorax201267323824322008189
  • WedzichaJASeemungalTACOPD exacerbations: defining their cause and preventionLancet2007370958978679617765528
  • MasoompourSMMohammadiAMahdaviazadHAdherence to the Global initiative for chronic obstructive lung disease guidelines for management of COPD: a hospital-base studyClin Respir J201610329830225308344
  • AlmagroPCabreraFJDiezJComorbidities and short-term prognosis in patients hospitalized for acute exacerbation of COPD: the EPOC en servicios de medicina interna (ESMI) studyChest201214251126113323303399
  • MiravitllesMCalleMSoler-CatalunaJJClinical phenotypes of COPD: identification, definition and implications for guidelinesArch Bronconeumol2012483869822196477
  • HuertaACrisafulliEMenendezRPneumonic and nonpneumonic exacerbations of COPD: inflammatory response and clinical characteristicsChest201314441134114223828375
  • RocaMRocaICMihaescuTLung cancer – a comorbidity in chronic obstructive pulmonary diseaseRev Med Chir Soc Med Nat Iasi201211641055106223700888
  • BarrechegurenMEsquinasCMiravitllesMThe asthma-chronic obstructive pulmonary disease overlap syndrome (ACOS): opportunities and challengesCurr Opin Pulm Med2015211747925405671
  • AdubatoSMenackerMACOs and the future of medicine: an interview with Morey Menacker, DOMD Advis20147246
  • ZekiAASchivoMChanAAlbertsonTELouieSThe asthma-COPD overlap syndrome: a common clinical problem in the elderlyJ Allergy (Cairo)2011201186192622121384
  • Martinez-GarciaMAde la Rosa CarrilloDSoler-CatalunaJJPrognostic value of bronchiectasis in patients with moderate-to-severe chronic obstructive pulmonary diseaseAm J Respir Crit Care Med2013187882383123392438
  • ChenYHSunYCBronchiectasis as a comorbidity of chronic obstructive pulmonary disease: implications and future researchChin Med J (Engl)2016129172017201927569224
  • MacNeeWSystemic inflammatory biomarkers and co-morbidities of chronic obstructive pulmonary diseaseAnn Med201345329130023110517
  • LarattaCRvan EedenSAcute exacerbation of chronic obstructive pulmonary disease: cardiovascular linksBiomed Res Int2014201452878924724085
  • FabbriLMLuppiFBegheBRabeKFComplex chronic comorbidities of COPDEur Respir J200831120421218166598
  • SorianoJBVisickGTMuellerovaHPayvandiNHansellALPatterns of comorbidities in newly diagnosed COPD and asthma in primary careChest200512842099210716236861
  • DoddJWCharltonRAvan den BroekMDJonesPWCognitive dysfunction in patients hospitalized with acute exacerbation of COPDChest2013144111912723349026
  • ManninoDMThornDSwensenAHolguinFPrevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPDEur Respir J200832496296918579551
  • ArosteguiIEstebanCGarcia-GutierrezSSubtypes of patients experiencing exacerbations of COPD and associations with outcomesPLoS One201496e9858024892936
  • HurstJRVestboJAnzuetoASusceptibility to exacerbation in chronic obstructive pulmonary diseaseN Engl J Med2010363121128113820843247
  • TashkinDPFrequent exacerbations of chronic obstructive pulmonary disease – a distinct phenotype?N Engl J Med2010363121183118420843256
  • WedzichaJABrillSEAllinsonJPDonaldsonGCMechanisms and impact of the frequent exacerbator phenotype in chronic obstructive pulmonary diseaseBMC Med20131118123945277
  • DonaldsonGCSeemungalTAPatelISAirway and systemic inflammation and decline in lung function in patients with COPDChest200512841995200416236847
  • BhowmikASeemungalTASapsfordRJWedzichaJARelation of sputum inflammatory markers to symptoms and lung function changes in COPD exacerbationsThorax200055211412010639527
  • SeemungalTAWilkinsonTMHurstJRPereraWRSapsfordRJWedzichaJALong-term erythromycin therapy is associated with decreased chronic obstructive pulmonary disease exacerbationsAm J Respir Crit Care Med2008178111139114718723437
  • Garcia-AymerichJFarreroEFelezMARisk factors of readmission to hospital for a COPD exacerbation: a prospective studyThorax200358210010512554887
  • Soler-CatalunaJJRodriguez-RoisinRFrequent chronic obstructive pulmonary disease exacerbators: how much real, how much fictitious?COPD20107427628420673037
  • MiravitllesMSoler-CatalunaJJCalleMA new approach to grading and treating COPD based on clinical phenotypes: summary of the Spanish COPD guidelines (GesEPOC)Prim Care Respir J201322111712123443227
  • AlbertRKConnettJBaileyWCAzithromycin for prevention of exacerbations of COPDN Engl J Med2011365868969821864166
  • PoolePJBlackPNMucolytic agents for chronic bronchitis or chronic obstructive pulmonary diseaseCochrane Database Syst Rev20063CD001287
  • FergusonGTAnzuetoAFeiREmmettAKnobilKKalbergCEffect of fluticasone propionate/salmeterol (250/50 microg) or salmeterol (50 microg) on COPD exacerbationsRespir Med200810281099110818614347
  • HoogendoornMFeenstraTLHoogenveenRTAlMMolkenMRAssociation between lung function and exacerbation frequency in patients with COPDInt J Chron Obstruct Pulmon Dis2010543544421191438
  • CarolanBJSutherlandERClinical phenotypes of chronic obstructive pulmonary disease and asthma: recent advancesJ Allergy Clin Immunol20131313627634 quiz 63523360757
  • LinCLSiuLKLinJCMannose-binding lectin gene polymorphism contributes to recurrence of infective exacerbation in patients with COPDChest20111391435120688922
  • ForemanMGDeMeoDLHershCPPolymorphic variation in surfactant protein B is associated with COPD exacerbationsEur Respir J200832493894418550614
  • WellsJMWashkoGRHanMKPulmonary arterial enlargement and acute exacerbations of COPDN Engl J Med20123671091392122938715
  • Sarinc UlasliSBozbasSSOzenZEOzyurekBAUlubayGEffect of thyroid function on COPD exacerbation frequency: a preliminary studyMultidiscip Respir Med2013816424079533
  • HuertaADonaldsonGCSinghRUpper respiratory symptoms worsen over time and relate to clinical phenotype in chronic obstructive pulmonary diseaseAnn Am Thorac Soc2015127997100425938279
  • MorrowJDQiuWChhabraDIdentifying a gene expression signature of frequent COPD exacerbations in peripheral blood using network methodsBMC Med Genomics20158125582225
  • OhYMSheenSSParkJHEmphysematous phenotype is an independent predictor for frequent exacerbation of COPDInt J Tuberc Lung Dis201418121407141425517804
  • SinghDFoxSMTal-SingerRBatesSRileyJHCelliBAltered gene expression in blood and sputum in COPD frequent exacerbators in the ECLIPSE cohortPLoS One201499e10738125265030